Adamantiades-Behçet disease: An enigmatic process with oral manifestations;Enfermedad de Adamantiades-Behçet: Un proceso enigmático con manifestaciones orales

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 11, Issue 1, 2006, Pages 6-11

  Eguia, Asier ^a   Villarroel, Mariana ^b   Martínez Conde, Rafael ^a   Echebarría, María Ángeles ^a   Aguirre, José Manuel ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Adamantiades Beh et disease; Aphthous stomatitis; Beh et disease; Oral ulcers; Vasculitis

Indexed keywords

ANALGESIC AGENT; ANTIINFECTIVE AGENT; BETAMETHASONE; CLOBETASOL; FLUOCINOLONE; PENTOXIFYLLINE; TRIAMCINOLONE; HLA ANTIGEN;

BEHCET DISEASE; CLINICAL FEATURE; DISEASE EXACERBATION; GEOGRAPHY; HUMAN; MOUTH ULCER; POPULATION RESEARCH; PREVALENCE; REMISSION; REVIEW; VASCULITIS; APHTHOUS STOMATITIS; IMMUNOLOGY; JAPAN; KOREA; PATHOLOGY; TURKEY (REPUBLIC);

BEHCET SYNDROME; HLA ANTIGENS; HUMANS; JAPAN; KOREA; PREVALENCE; STOMATITIS, APHTHOUS; TURKEY;

EID: 33644808842     PISSN: 16984447     EISSN: 16986946     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Kontogiannis V, Powell RJ. Behçet's disease. Postgrad Med J 2000;76:629-37.
2. Lee LA. Behcet disease. Semin Cutan Med Surg 2001;20:53-7.
3. Barnes CG, Yazici H. Behcet's Syndrome. Rheumatology 1999;38:1171-6.
4. Dimakakos PB, Tsiligiris B, Kotsis T. The physician B. Adamantiades and his contribution to the disease Adamantiades-Behcet. Int Angiol 1999;18:176-81.
5. Zouboulis CC. Epidemiology of Adamantiades-Behçet's disease. Ann Med Int 1999;150:488-98.
6. Jaber L, Milo G, Halpern GJ, Krause I, Weinberger A. Prevalence of Behçet's disease in an arab community in Israel. Ann Rheum Dis 2002;61:365-6.
7. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behçet's disease, the silk road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999;54:213-20.
8. Zouboulis C, Kotier I, Djawari D, Kirch W, Kohl P, Ochsendorf FR et al. Epidemiological features of Adamantiades- Behçet's disease in Germany and in Europe. Yonsei Med J 1997;38:411-22.
9. Yacizi H, Yurdakul S, Tüzün Y. Influence of age and onset and patient's sex on the prevalence and severity of manifestations of Behçet's disease. Ann Rheum Dis 1984;43:783-9.
10. Onder M. Gurer MA. The multiple faces of Behçet's disease and its aetiological factors. J Eur Acad Dermatol Venereol 2000;15:126-36.
11. Lehner T, Welsh KI, Batchelor JR. The relationship of HLA-B and DR phenotypes to Behçet's syndrome, recurrent oral ulceration and the class of immune complexes. Immunology 1982;47:581-7.
12. Kim EH, Mok JW, Bang D, Lee ES, Lee S, Park K. Intercellular adhesion molecule-1 polymorphisms in Korea patients with Behçet's disease. J Korean Med Sci 2003;18:415-8.
13. Sun A, Hsieh RP, Chu CT, Wang JT Liu BY, Chiang CP. Some specific human leukocyte antigen (HLA)-DR/DQ haplotypes are more important than individual HLA-DR and -DQ phenotypes for the development of mucocutaneous type of Behçet's disease and for disease shift from recurrent aphthous stomatitis to mucocutaneous type of Behçet's disease. J Oral Pathol Med 2001;30:402-7.
14. Meador R, Ehrlich G, Von Feldt JM. Behçet's disease: immunopathologic and therapeutic aspects. Curr Rheumatol Rep 2002;4:47-54.
15. Emmi L, Brugnolo F, Marchione T. Pathogenesis and therapy of Behçet's disease. Ann Ital Med Int 1997;12:20-5.
16. Behçet H. Uber rezidivierende, aphtose, durch ein virus verursachte. Geschwure am Mund, am Auge und an den Genitalen. Dermatol Wochenchir 1937;36:1152-7.
17. Bang D. Clinical spectrum of Behçet's disease. J Dermatol 2001;28: 610-3.
18. Rizvi SW, McGrath H Jr. The therapeutic effect of cigarette smoking on oral/genital aphtosis and other manifestations of Behçet's disease. Clin Exp Rheumatol 2001;19:77-8.
19. Cappele O, Nicolas J, Bottet P, Bensadoum H. Urological manifestations of Behçet's disease. Prog Urol 2003;77:329-31.
20. Lee E, Bang D, Lee S. Dermatologic manifestations of Behçet's disease. Yonsei Med J 1997;38:380-9.
21. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgacioglu M. Uveitis in Behçet disease: An analysis of 880 patients. Am J Ophtalmol 2004;138:373-80.
22. Silva A, Altintas A, Saip S. Behcet's syndrome and the nervous system. Curr Opin Neurol 2004;17:347-57.
23. Koc Y, Güllü I, Akpek G, Akpolat T, Kansu E, Kiraz S et al. Vascular involvement in Behçet's disease. J Rheumatol 1992;19:402-10.
24. Kyu H. Cheon KS. The clinical significance of a pathergy reaction in patients with Behçet's disease. J Korean Med Sci 2002;17:371-4.
25. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
26. Whallet AJ, Thurairajan G, Hamburger J, Palmer RG, Murray PI. Behçet's syndrome: a multidisciplinary approach to clinical care. Q J Med 1999;92: 727-40.
27. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of Interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-35.
28. Sakane T, Takeno M. Current therapy in Behçet's disease. Skin Therapy Lett 2000;5:3-5.
29. Barrons RW. Treatment strategies for recurrent oral aphtous ulcers. Am J Health Syst Pharm 2001;58:41-53.
30. Yacizi H, Basaran G, Hamuryudam V, Hizli N, Yurdakul S, Mat C et al. The ten-year mortality in Behçet's syndrome. Br J Rheumatol 1996;35:139-41.